MedTrace Logo

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.

Conditions

Interventions

DRUG

PF-06826647 tablet

PF-06826647 tablet for oral administration

DRUG

PF-06826647 oral suspension

PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)

OTHER

Placebo oral solution/suspension

placebo oral solution for the single ascending dose, first cohort only

OTHER

Placebo tablet

Matching placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-14
Primary Completion
2019-01-25
Completion
2019-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210961 on ClinicalTrials.gov